Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GlycoModels

Financiado

Cerrado

3D glyco engineered models to address the role of glycosylation in gastric cance...

3D glyco engineered models to address the role of glycosylation in gastric cancer clinical management Gastric cancer is an important health problem, being the fifth most common cancer and the third leading cause of cancer death. Its late diagnosis accompanied with a bad prognosis keeps this malignancy among the most deadly. After... ver más

30/04/2019

IPATIMUP INSTITUT...

149K€

Presupuesto del proyecto: 149K€

Líder del proyecto

IPATIMUP INSTITUTO DE PATOLOGIA E IMUNOLOGIA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-04-30

MSCA-IF-2016: Individual Fellowships

I+D

Cerrada hace 8 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

IPATIMUP INSTITUTO DE PATOL...

148.64K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ROSETTA Deciphering the Role of aberrant glycOSylation in the rEspon... 176K€ Cerrado

GlyCanDrug A training network on the design of precision therapeutics t... Cerrado

CarboMed Development of carbohydrate based anticancer agents 150K€ Cerrado

BCSC-ST Breast cancer stem like cells specific vulnerabilities focu... 195K€ Cerrado

ONCOINTRABODY Targeting common oncogenes with intracellular monobodies 2M€ Cerrado

onCOMBINE Towards evidence based combinations of approved and novel ca... 2M€ Cerrado

Duración del proyecto: 26 meses Fecha Inicio: 2017-02-14
Fecha Fin: 2019-04-30

Líder del proyecto

IPATIMUP INSTITUTO DE PATOLOGIA E IMUNOLOGIA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 149K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Gastric cancer is an important health problem, being the fifth most common cancer and the third leading cause of cancer death. Its late diagnosis accompanied with a bad prognosis keeps this malignancy among the most deadly. After generations of cancer therapy based on chemical drugs causing severe side effects and limited efficiency, cancer treatment undergoes a paradigm shift towards targeted therapy, employing both monoclonal antibodies and small molecule inhibitors of receptor tyrosine kinase activity, as the most promising tool for the years to come. However, there are numerous patients that do not respond to these novel treatments due to mutations in downstream signalling pathways or to undefined molecular mechanisms. Protein glycosylation has been shown to modulate cellular receptor functions and alter antibody binding affinities and therefore foreshadows to play a major role in cancer therapy resistance. The GlycoModels project aims to identify glycan alterations on cell receptors that lead to targeted therapy resistance of gastric tumours. Using cutting-edge gene editing techniques, gastric cancer cell lines will be glyco-engineered to express hallmark glycan epitopes and applied in 3D-culture systems as advanced models mimicking the tumour microenvironment. These 3D-GlycoModels will display differential response to treatment with the most promising targeted therapy agents for key cell receptors (HER2, VEGFR, MET and RON) involved in growth, progression, and spread of cancer. In-depth analysis of the GlycoModels, covering glycan characterisation of the cell receptors, disclosing activated signalling pathways, and transcriptomics will unveil our understanding on driving mechanisms in therapy resistance and the glycosylation patterns involved. The structural validation of these glycoforms in human samples will deliver new biomarkers to be used in personalised therapy selection and thus, improve the outcome of advanced gastric cancer patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores